{"id":"candesartan-hct","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hyperkalemia (candesartan component)"},{"rate":null,"effect":"Hypokalemia (HCT component)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hyperuricemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Candesartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels, causing vasodilation and reduced blood pressure. Hydrochlorothiazide (HCT) is a thiazide diuretic that increases sodium and water excretion, further reducing blood volume and blood pressure. The combination provides complementary antihypertensive effects.","oneSentence":"Candesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide acts as a diuretic to reduce fluid volume.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:03.708Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Reduction of cardiovascular events in patients with hypertension"}]},"trialDetails":[{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT00468923","phase":"PHASE4","title":"Heart Outcomes Prevention Evaluation-3","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2007-05","conditions":"Cardiovascular Disease, Stroke","enrollment":12705},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00081731","phase":"PHASE3","title":"Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions","status":"COMPLETED","sponsor":"Baim Institute for Clinical Research","startDate":"2004-04","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypertension, Renovascular","enrollment":947},{"nctId":"NCT00775814","phase":"PHASE4","title":"Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-10","conditions":"Obesity, Hypertension","enrollment":188},{"nctId":"NCT00434967","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Hypertension","enrollment":2207},{"nctId":"NCT00621153","phase":"PHASE4","title":"Candesartan Effect in Second Stage Arterial Hypertension","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-02","conditions":"Stage II Hypertension","enrollment":214},{"nctId":"NCT00383929","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Hypertension","enrollment":1979},{"nctId":"NCT00607633","phase":"","title":"Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Essential Hypertension, Left Ventricular Hypertrophy","enrollment":686},{"nctId":"NCT00608153","phase":"","title":"Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Essential Hypertension","enrollment":1773}],"_emaApprovals":[],"_faersSignals":[{"count":18,"reaction":"ACUTE KIDNEY INJURY"},{"count":14,"reaction":"HYPOTENSION"},{"count":12,"reaction":"DRUG INTERACTION"},{"count":12,"reaction":"NAUSEA"},{"count":12,"reaction":"OFF LABEL USE"},{"count":9,"reaction":"HYPONATRAEMIA"},{"count":9,"reaction":"VOMITING"},{"count":8,"reaction":"DIZZINESS"},{"count":8,"reaction":"FATIGUE"},{"count":8,"reaction":"INFLAMMATION"}],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Candesartan/HCT","genericName":"Candesartan/HCT","companyName":"Population Health Research Institute","companyId":"population-health-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Candesartan/HCT is a medication used to treat conditions such as essential hypertension, left ventricular hypertrophy, and cardiovascular disease. It works as a small molecule antagonist that blocks the type-1 angiotensin II receptor, a mechanism that helps lower blood pressure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}